Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia

1. A method of modulating, ameliorating or stabilizing at least one physical parameter of a cancer, or a symptom thereof, and/or delaying the onset of a cancer, said cancer being from myeloproliferative neoplasia, chronic myeloid leukemia and acute myeloid leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the following structure:

2. A method of modulating, ameliorating or stabilizing at least one physical parameter of a cancer, or a symptom thereof, and/or delaying the onset of a cancer, said cancer being selected from myeloproliferative neoplasia, chronic myeloid leukemia and acute myeloid leukemia, comprising administering to a patient in need thereof a:

in combination with an agent that inhibits JAK2 kinase, BCR-ABL kinase, or histone deacetylase.

3. The method of claim 1 , wherein the cancer is selected from myeloproliferative neoplasia.

4. The method of claim 1 , wherein the cancer is selected from chronic myeloid leukemia.

5. The method of claim 1 , wherein the cancer is selected from acute myeloid leukemia.

6. The method of claim 2 , wherein the cancer is selected from myeloproliferative neoplasia.

7. The method of claim 2 , wherein the cancer is selected from chronic myeloid leukemia.

8. The method of claim 2 , wherein the cancer is selected from acute myeloid leukemia.

9. The method of claim 2 , wherein an agent that inhibits JAK2 kinase is administered.

10. The method of claim 9 , wherein the agent that inhibits JAK2 kinase is N-tert-butyl-3-[[5-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]benzene-sulfonamide.

11. The method of claim 2 , wherein an agent that inhibits BCR-ABL kinase is administered.

12. The method of claim 2 , wherein an agent that inhibits histone deacetylase is administered.

13. The method of claim 1 , wherein said cancer symptom is ameliorated.

14. The method of claim 1 , wherein said cancer symptom is modulated.

15. The method of claim 1 , wherein said cancer symptom is stabilized.

16. The method of claim 1 , wherein the onset of said cancer is delayed.

17. The method of claim 2 , wherein said cancer symptom is ameliorated.

18. The method of claim 2 , wherein said cancer symptom is modulated.

19. The method of claim 2 , wherein said cancer symptom is stabilized.

20. The method of claim 2 , wherein the onset of said cancer is delayed.